drug · antibody drug conjugate
loncastuximab tesirine
Marketedupdated 3mo agoby $ADCT ADC Therapeutics SA🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Antibody drug conjugate drug with a maximum clinical stage of Approval (across all indications), with 4 approved and 5 investigational indications.
indications
investigational
DLBCL
targets
B-lymphocyte antigen CD19
all catalysts(5)
approval · 5
Apr 23, 2021
approval
$ADCT1.0500-5.41%
ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) — FDA approval
loncastuximab tesirine
→
Oct 12, 2022
approval
$ADCT1.0500-5.41%
ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) — FDA approval
loncastuximab tesirine
→
Oct 12, 2022
approval
$ADCT1.0500-5.41%
ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) — FDA approval
loncastuximab tesirine
→
Jan 16, 2026
approval
$ADCT1.0500-5.41%
ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) — FDA approval
loncastuximab tesirine
→
Feb 20, 2026
approval
$ADCT1.0500-5.41%
ZYNLONTA (LONCASTUXIMAB TESIRINE-LPYL) — FDA approval
loncastuximab tesirine
→
Trials studying loncastuximab tesirine
- phase3Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- phase2Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
- phase1A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)
- phase2Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
- phase3A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
- phase1Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)
- phase2Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL)
- phase2Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
News(5)
- Aura, Schrödinger trim workforcesFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 7h ago
- BioNTech picks Sobi CEO Oelkers to lead as founders plot new mRNA biotechBioNTech’s leadership transition was announced earlier this year, with CEO Ugur Sahin and CMO Özlem Türeci leaving to start a new mRNA company. Guido Oelkers of Swedish Orphan Biovitrum AB will tak…biospace · 8d ago
- An ADC specialist sinks on safety concerns for blood cancer drugShares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”biopharma_dive · 2mo ago
- ADC Therapeutics' confirmatory data for Zynlonta muddied by death ratesADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...endpoints · 2mo ago
- Fierce Biotech Layoff Tracker 2026: Aura loses 20% of staffers; aTyr shrinks by 60%As always, if you know of layoffs occurring at a biotech, please reach out to the Fierce Biotech editorial team.fiercebiotech · 7mo ago
Data sources
last refreshed 29m ago
Found something off?
comments(0)
5-min edit window · permanent after that